1. Netflix's The Great Indian Kapil Show: Navjot Singh Sidhu is back after 5 years of exit, Archana Puran Singh says, 'He’s taken over my...'  Firstpost
2. Did you know! Navjot Singh Sidhu was ousted from The Kapil Sharma Show for this reason  The Times of India
3. Navjot Singh Sidhu makes a roaring comeback; Archana Puran Singh worried about her The Great Indian Kapil Show throne  Hindustan Times
4. The Great Kapil Sharma Show: Navjot Sidhu shares his fast-track fatherhood plan. Kapil’s response is too f  The Economic Times
5. Navjot Singh Sidhu shares BTS pics from The Great Indian Kapil's show set with Archana Puran Singh and...  Moneycontrol

1. Church of England head Justin Welby who married Prince Harry and Meghan Markle resigns over pedophile scandal  Hindustan Times
2. Archbishop of Canterbury, Trump critic Justin Welby resigns. What is the sex abuse scandal?  The Times of India
3. Video | UK Church Abuse Scandal: Head Of Church Of England Steps Down  NDTV
4. ‘Church in crisis’: what the papers say about the archbishop of Canterbury’s resignation  The Guardian
5. World News Today Live Updates on November 13, 2024 : Archbishop of Canterbury Justin Welby resigns amid sexual abuse case—Who is he? What's the scandal? All you need to know  Mint

1. Jharkhand election 2024 live: Over 13% voter turnout in 43 seats till 9am  Hindustan Times
2. Jharkhand Election 2024 Live Updates: Former CM, BJP candidate Champai Soren casts vote  The Times of India
3. Vote to protect rights, strengthen Constitution: Rahul to Jharkhand voters  The Hindu
4. Jharkhand elections phase 1: NDA vs INDIA bloc face-off with crucial tribal votes in play  India Today
5. Think of forming inclusive government not one that divides: Kharge to voters  Deccan Herald

Bollywood star Suniel Shetty sustained a minor injury on the sets of the web series ‘Hunter 2’

‘Idli Kadai,’ Dhanush’s fourth directorial project, has music scored by GV Prakash Kumar

Tentatively called D55, the film is produced by Sushmita Anbuchezian under the Gopuram Films banner

Promising to be inspiring, ‘Vijay 69’ turns out like a mildly entertaining episode in Anupam Kher’s popular play, ‘Kucch Bhi Ho Sakta Hai’

While the gimmick of multiple frames wears thin fairly quickly, this mixed box of chocolates from Robert Zemeckis rides on Tom Hanks’ quiet charm

The film will mark Geetu’s third directorial after ‘Liar’s Dice’ and ‘Moothon’

The supporting cast ‘Thudarum’ includes Binu Pappu, Maniyanpilla Raju, Farhaan Faasil, and Thomas Mathew

‘Jai Hanuman’, a sequel to ‘HanuMan’, will have Rishab Shetty in the lead and the movie will be produced by Mythri Movie Makers

‘Game Changer’ also stars Kiara Advani, Anjali, Samuthirakani, SJ Suryah, Srikanth and Sunil

From towering cutouts to fans dancing to the iconic Oscar-winning “Naatu Naatu” and the latest “Raa Macha Macha”, the teaser launch event was Ram Charan’s humble exhibition of the northern territories he has conquered in the wake of ‘RRR’

The show originally aired on Doordarshan in 1997, became one of India’s most beloved superhero shows, running for over 450 episodes

This follow-up to last year’s ‘Mission: Impossible — Dead Reckoning Part One’, which earned over $571 million globally, is expected to draw blockbuster attention as one of the summer’s biggest releases

Released in 1993 and directed by the Abbas-Mustan duo, ‘Baazigar’ was a game-changer for Shah Rukh Khan’s career, marking his debut in an anti-hero role that diverged sharply from typical Bollywood protagonists of that era

Aamir Khan recently kicked off the campaign at New York’s Indian restaurant, The Bungalow, where he was joined by Kiran Rao and hosted by chef Vikas Khanna

Back in December, I reviewed Square Enix’s monster collecting RPG Dragon Quest Monsters: The Dark Prince on Switch. I loved …

Continue reading "‘Dragon Quest Monsters: The Dark Prince’ iOS Review – Much Better Than Switch, but Lacking in Two Ways"

A lot of folks got into the SaGa series a long time ago through its many releases on prior console …

Continue reading "Romancing SaGa 2: Revenge of the Seven Interview With Game Producer Shinichi Tatsuke and Steam Deck Hands-On Preview"

Company expects to be cash flow positive in the next two quarters.

Hurricane Milton flooded parts of the Tampa Bay region just days after Hurricane Helene made landfall nearby.

As Lineker prepares for life away from the BBC, his podcast empire is proving there is life away from football

A group representing hunters in the Nordic countries says it’s more optimistic than ever that the European Union will lift a longtime ban on trading seal products that deprived Canadian sealers of their primary market.

While reading through the list of Grammy nominees earlier I came across quite a surprise. There, competing for record of the year alongside the likes of Beyoncé's Texas Hold 'Em and Chappell Roan's Good Luck Babe, was Now and Then by The Beatles. No, to my dismay, this isn't a time travel situation, but the result of AI. 

So, here's the story of how The Beatles got nominated for two Grammys — they also snagged a best rock performance nod — 50 years after formally breaking up. It starts with a demo John Lennon recorded in the 1970s that was given to Paul McCartney, Ringo Starr and George Harrison for inclusion on the The Beatles Anthology, released in 1995. While other tracks like Free as a Bird and Real Love made it on, technology wasn't advanced enough to separate Lennon's vocals and piano without reducing the recording's quality. 

But, last year McCartney and Starr used modern machine learning technology to pull Lennon's vocals for a new track. Now and Then, released in November 2023, includes McCartney on bass, Starr on the drums, Lennon's vocals and a guitar in Harrison's style (a 1995 recording of him makes up some of the background rhythm guitar. You can watch a documentary about making the track here. 

Unsurprisingly, the song is said to be the last from the Beatles. We'll have to wait until the awards show in February to see whether or not AI will help them win another Grammy. 

This article originally appeared on Engadget at https://www.engadget.com/ai/the-beatles-are-nominated-for-two-grammys-thanks-to-ai-150004467.html?src=rss

Netflix is crowing that its ad-supported tier now boasts 70 million users throughout the globe, as reported by Variety. The company announced 40 million users back in May, so this is some real growth. The streamer has been slowly ramping up its ad tier, going all the way back to 2022.

Amy Reinhard, president of advertising at Netflix, says that the company continues “to see steady progress across all countries’ member bases.” She also noted that over 50 percent of new Netflix sign-ups are for these ad-supported plans. The transformation of streaming into regular TV is nearly complete.

There’s one major potential caveat. The company released the aforementioned data regarding new sign-ups, which is impressive, but there isn’t any information regarding pre-existing customers. It’s highly possible a whole lot of people downgraded from a premium tier to an ad-supported tier.

I’m one of them. I don’t mind watching an ad or two as I mindlessly stuff food down my gullet while pseudo-watching an episode of The Diplomat or The Circle. In other words, there’s an argument to be made that the ad-supported tier could be eating into the more expensive offerings.

There’s also an argument to be made that this year’s growth spurt for the ad-supported tier could attract companies with deeper ad-spending budgets, thus making up the difference. Netflix is airing live NFL broadcasts on Christmas Day, and it says it has already sold out all available commercial inventory. The streamer is actually betting big on live streams, with wrestling events, cooking shows and talk shows all airing in the near future. The company’s recent forays into audience measurement and the ad-tech space should help entice sponsors for these events.

Netflix even has plans for “themed” advertisements with certain shows. The next season of Squid Game will include a three-part linked commercial by Kia. Nothing makes me want to buy a car more than a deadly dystopian bloodsport that seems closer and closer to the real world by the day.

This article originally appeared on Engadget at https://www.engadget.com/entertainment/tv-movies/netflixs-ad-tier-has-attracted-more-than-70-million-subscribers-162011582.html?src=rss

The initial buzz for Apple’s mixed-reality headset has died down, but new apps and experiences are still arriving for consumers who plunked down $3,500. The UK broadcaster Channel 4 just dropped a dedicated streaming app for the headset, which lets users watch stuff in “ground-breaking cinema-style.”

Channel 4 is the first UK broadcaster to take this step. The app leverages the tech inside the headset to overlay streaming content on the real world, which allows for a “full-screen viewing experience” of stuff like The Great British Bake Off and Taskmaster, in addition to multi-screen view.

Speaking of Taskmaster, the broadcaster also announced an environment based on the comedy game show. Environments on the AVP transform the world around the user, so people can watch Taskmaster while sitting in a room inspired by Taskmaster (cue that Xzibit Yo Dawg meme.) Other streaming apps have their own environments. Paramount+ offers one based on SpongeBob Squarepants and Disney+ now includes one set in Iceland.

This app doesn’t feature access to the recently-released Taskmaster VR experience. That one’s still tied to Steam VR and Meta Quest. By most accounts, it’s a pretty bad game, so the Vision Pro isn’t missing much.

This article originally appeared on Engadget at https://www.engadget.com/ar-vr/channel-4-in-the-uk-now-has-a-dedicated-app-for-apple-vision-pro-200027166.html?src=rss

Le grand requin blanc attaque souvent ses proies par en dessous, confondant parfois la silhouette d’un surfeur avec celle d’un phoque.

The prolific British author discussed his latest book on Bookends with Mattea Roach.

La jeune artiste de 20 ans domine les palmarès radio depuis trois semaines.

Une ancienne boîte de poulet St-Hubert, retrouvée par hasard dans l’entretoit d’un chalet, a été remise à la famille Martin en échange d'un don.

Canada's unemployment rate was unchanged in October at 6.5 per cent, while job growth was little changed from the previous month, Statistics Canada said Friday.

Chris Martin a intrigué les badauds lundi en embrassant le tarmac de l’aéroport de Sydney.

Flying has never been safer for Australians on commercial aircraft, according to a new report from the ATSB.

The Indian pharmaceutical industry is advocating for enhanced fire safety measures and improved insurance coverage for employees working in pharmaceutical facilities.

The outcome of the 2024 U.S. presidential election could reshape policies from health care at home to nuclear proliferation abroad

Efficient machines, paper ballots and human checks make the U.S. voting system robust

The outcome of the 2024 U.S. presidential election could set the climate agenda, reshape public education and shift the dynamics of global science collaboration.

What was once fair under the law may become unfair when science changes. The law must react to uphold due process

A fee created to push oil and gas companies to plug methane leaks could be axed by the incoming Trump administration, hampering efforts to curb the potent greenhouse gas

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you:

• Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble

• Optum Rx joins the private label biosimilar bandwagon

• Biosimilars boom for provider-administered drugs

• Fresh evidence of how copay accumulators hurt patients

Plus, words of wisdom from Cencora's soon-to-be-former CEO Steve Collis.

P.S. Join my more than 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community.

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Read more »

Drug Channel Institute is pleased to announce The Drug Channels 2025 Video Webinar Series.

Join Dr. Adam J. Fein for three live video webinars during 2025. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia.

During these events, Dr. Fein will address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more. He’ll share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your current learning and a touchpoint for the future.

The three events are scheduled for 12:00 p.m. to 1:30 p.m. ET on the following dates:

• April 4, 2025

• June 20, 2025

• December 12, 2025 (Drug Channels Outlook 2026)

For 2025, we are offering a Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price. Please contact Paula Fein (paula@drugchannels.net) for details.

Read on for full details on pricing, including substantial discounts for multiple sites.

P.S. If you're not familiar with our webinars, click here to watch brief excerpts from our video webinars.
Read more »

Today’s guest post comes from Angie Franks, Chief Executive Officer of Kalderos.

Angie discusses how the Maximum Fair Price provision of the Inflation Reduction Act of 2022 will challenge providers, pharmacies, and manufacturers. She explains how Kalderos’ Truzo platform could reduce duplicate claims and address compliance issues.

To learn more, register for Kalderos’ October 25 webinar Cracking the MFP Code: How Flexible Technology Helps You Navigate an Evolving Landscape.

Read on for Angie’s insights.
Read more »

A new survey of plan sponsors sheds light on their satisfaction with transparency at large and small pharmacy benefit managers (PBMs).

As you will see, clients remain slightly more satisfied with the perceived transparency of smaller PBMs compared with the Big Three PBMs—CVS Caremark, Express Scripts, and Optum Rx.

However, plan sponsors are dissatisfied with transparency about how both large and small PBMs make money. Smaller PBMs have an edge, but it’s narrower than you might think.

Perhaps PBMs’ clients are unable or unwilling to negotiate better deals, write more effective contracts, and switch to more satisfying relationships. Or maybe they don’t mind the current system, despite the challenges for patients. Some argue that transparency could swoop down to solve this problem. Riddle me this: Should we watch what plan sponsors say, or what they do?

Read on to see what you think of my arguments below. Then, click here to share your thoughts with the Drug Channels community.
Read more »

Informa Connect’s Trade and Channel Strategies
December 10-12, 2024 at the W Hotel in Philadelphia, PA
Drug Channels readers save 10% with code 24DC10*

Pharmacy and distribution models are growing increasingly complex. Stop running in circles—It’s time to unlock proven strategies to propel market access.

What is the secret to success? Trade and Channel Strategies is bringing together industry experts to deliver specific strategies and talk best practices in tackling the latest industry challenges.

As the landscape rapidly evolves, there are only two choices—Adapt or risk falling behind. With policy changes and market fluctuations, specifically surrounding the DSCSA and IRA, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of innovations within the pharmacy sector, there has never been a more important time for industry to unite. A program driven by market dynamics and led by champions of channel strategy, join your peers now to master the complexities of pharmacy and distribution models to accelerate market access—It's all happening December 10-12.

Why do trade and channel professionals choose this pivotal event?

The challenge of staying viable among shifting market dynamics while meeting business objectives is heavy. Professionals are left with many questions, including:

• How will the new administration affect the distribution channel?
• Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?
• Does the DSCSA deadline change affect my organization? Am I still prepared?

Join the experts for three dedicated days of collaborative discussions that will give you the answers to these questions and so many more. Leaders in the landscape are uniting and will dive into the top trends for innovative distribution, integrated pharmacy models and talk the truth about the future of trade.

WHAT CAN YOU EXPECT?

Vital insights from industry’s leading pharmacy and distribution experts, including:

• Bill Roth, Senior Vice President of Consulting, Blue Fin Group, An IntegriChain Company
• Patrick Lupo Group Vice President, Pharmacy Trade and Specialty, Walgreens
• Amanda Salindong, Associate Director, Channel & Distribution, Alnylam Pharmaceuticals
• Chris Rocco, Senior Director, Market Access Data, Reporting & Analytics, GSK
• Eliane Maalouf, Director Trade and Fulfillment, Mass General Brigham Specialty Pharmacy
• Stephanie Wirkes, Head of Distribution and Strategy Execution, Bayer
• John Harlow, Chief Commercial Officer, Melinta Therapeutics
• Aria Cohen, Vice President, Head of Market Access, Alkeus Pharmaceuticals, Inc.
• Elizabeth Cherry, Program Director for Trade Relations, Vanderbilt Specialty Pharmacy
• Danielle Bryan, PharmD, CSP, Program Director, Specialty Pharmacy Trade Relations, Vanderbilt University Medical Center
• Thomas Scalone, Director, Trade Strategy and Operations, Bristol Myers Squibb
• Dina Lynch, VP, Market Access and Reimbursement, Renibus Therapeutics
• And more!

Tackle the hottest topics facing industry right now, including:

• Keynote Address: Access and Channel 2024 In-Review and Preview of 2025
• Pharmacy Evolved—Aligning Commercialization to the Changing Pharmacy Channel
• Advanced Trade Leaders Executive Session
• Navigate and Operationalize the IRA
• Focused Multi-Track Offerings:
  • Supply Chain, Distribution and Logistics
  • Pharmacy Models and Reimbursement Strategies
  • Data, Innovation and Analytics
  • Health Systems and Pharma Partnering Symposium
• Balancing the GTN Bubble with Market Access Priorities
• What’s Happening in Retail—Brick and Morter, Home Delivery and Cash Pay Pharmacies
• Navigating Post Deadline Challenges—DSCSA Compliance and Serialization Updates
• Four Roundtable Breakout Discussions:
  • What Good Looks Like in a 3PL/Manufacturer Partnership
  • Optimizing Healthcare Partnerships
  • Women in Trade
  • GLP-1s and New Product Archetypes
• Actions Needed to Mitigate and Prevent Drug Shortages
• Case Study: Master Your Organization Chart—Ensuring Higher Cross Functional Interactions
• Three Interactive Workshops:
  • Trade 101
  • Advanced Trade Leaders Executive Session
  • Health Systems Fundamentals
• And more!

Exclusive Offer—Download the agenda and register today—Be sure to use your exclusive promo 24DC10 to save 10% off* of your registration.

See you there!

* Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.

---

The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).

Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats:

• Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy

• Vampiric! Prior authorization sinks its fangs into providers’ time

• Wicked! How the IRA will put a stake through specialty physician practices

• Eerie! Google’s monstrous AI podcasts leave me petrified

• Zoinks! Join the vampire hunters at Drug Channels Institute

Plus, Dr. Glaucomflecken tells us a frightening tale of copayments.

P.S. Stretch out your arms and join the ever-growing zombie horde who shamble after me on LinkedIn. You’ll find my ghostly rantings along with commentary from the undead hordes in the DCI community.
Read more »

Adam J. Fein, Ph.D., president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar:

Friday, December 13, 2024,

from 12:00 p.m. to 1:30 p.m. ET

This post describes the event and explains how to purchase a registration. (Or, just click here to order.) The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.

This event is part of The Drug Channels 2024 Video Webinar Series. (Please note that our December 2024 webinar is *not* included with next year’s 2025 Video Webinar Series.)

WHAT YOU WILL LEARN

Join Dr. Fein as he helps you and your team get ready for 2025 by outlining key issues and uncertainties that will surely affect your planning. This event can be both a capstone of your annual learning and a touchpoint for the future. DCI’s Outlook webinars have proven to be reliable and informative guides to crucial aspects of the ever-evolving healthcare industry.

During the event, Dr. Fein will share his latest thinking and projections on a wide range of topics, including:

• Latest predictions for the Inflation Reduction Act

• Expectations for the Medicare Part D market in 2025 and beyond

• Update on 340B Drug Pricing Program’s controversies

• Impact of the new Trump administration and Congress on the drug channel

• Vertical integration and consolidation trends—and prospects for dis-integration and de-consolidation

• The state of biosimilar markets

• What’s next for PBMs’ private label products and GPOs

• Retail pharmacy’s future

• Prospects for direct-to-patient channels

• What’s ahead for discount cards and cash-pay pharmacies

• The outlook for state and federal legislation on PBMs and the drug channel

• Gross-to-net bubble developments

• And much more!

PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last at least 90 minutes to accommodate audience questions.

As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will draw from exclusive information found in DCI's economic reports .

Read on for full details on pricing and registration.
Read more »

The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact. Amidst the celebrations, a reporter asked me a provocative question: can we afford more orphan drugs costing hundreds of thousands of dollars per year? FDA Matters answered “yes.” However, I added a caveat that should worry everyone eager for orphan drugs to succeed. When genomics and personalized medicine become successful, this will multiply the number of rare diseases and the overall cost of orphan drugs, perhaps beyond what the system can bear.

Two former board chairs of the Coalition for Healthcare Communication (CHC) were named as the Medical Advertising Hall of Fame (MAHF) 2025 inductees – Sharon Callahan, former Chief Client Officer at Omnicom Health Group (OHG), and Nick Colucci, former Chairman and CEO of Publicis Health/COO of Publicis Groupe North America. The inductees will be honored […]